个性化蓝色丰富白光干预对轻度和中度阿尔茨海默病的休息活动和光照节奏的影响
Seong Jae Kim1, Jung Hie Lee2,3, Jae-Won Jang4
1Department of Psychiatry, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Republic of Korea.
Psychiatry investigation
|November 24, 2023
概括
个性化光疗可以改善阿尔茨海默病 (AD) 患者的休息活动和光照模式. 这种干预有助于减少节律的碎片化,有利于睡眠质量和日常生活.
科学领域:
- 时间生物学 时间生物学
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 经常与休息活动节奏 (RAR) 和光照节奏 (LER) 的中断有关,导致睡眠质量差和失眠.
- 这些昼夜节律障碍显著影响了阿尔茨海默氏症患者的日常功能和生活质量.
研究的目的:
- 评估个性化的光干预对轻度至中度阿尔茨海默病 (AD) 患者的休息活动节奏 (RAR) 和光照节奏 (LER) 的有效性.
主要方法:
- 一项单盲研究,涉及有睡眠障碍的AD患者,分为实验组 (EG) 接受个性化光疗和对照组 (CG) 佩戴蓝色减光太阳镜.
- 干预包括两周每天暴露1小时的光线,时间相对于个体暗光黑激素的发作而定.
- 动图被用来记录起始时的睡眠和活动模式,干预后立即干预,干预后四周.
主要成果:
- 干预后四周观察到休息活动节律 (RAR) 的日内变化 (IV) 的显著减少 (p=0.039).
- 在干预后立即注意到光照节奏 (LER) 的日内变化 (IV) 趋势下降 (p=0.052).
结论:
- 个性化照明干预,不管是蓝色丰富的光源,证明了在阿尔茨海默病患者中减轻休息活动和光照节奏碎片化的潜力.
- 研究结果表明,这种方法可以帮助稳定日常节律,有可能改善阿尔茨海默症患者的睡眠和整体幸福感.
相关概念视频
Alzheimer's Disease: Treatment
196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
Alzheimer's Disease: Overview
496
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
496


